FindTrial
Sign In

UB-VV400

GENETIC2 trials

Sponsors

Nanjing IASO Biotechnology Co., Ltd., Umoja Biopharma

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)Grade 3b Follicular LymphomaHigh Grade B Cell LymphomaLarge B-cell LymphomaLymphoma Non-HodgkinLymphoma, B CellPrimary Mediastinal B Cell LymphomaRichter Transformation Lymphoma

Phase 1

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
RecruitingNCT06743503
Nanjing IASO Biotechnology Co., Ltd.Large B-cell Lymphoma
Start: 2025-04-11End: 2030-07-31Target: 70Updated: 2025-09-18
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Not yet recruitingNCT07735533
Umoja BiopharmaLymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma +4
Start: 2026-08-01End: 2031-08-01Target: 274Updated: 2026-08-17